KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks.
Completion of Clinical Portion Represents Critical Milestone Towards Commercialization
Nasal Opioid Abuse Being Explored for PF614
Data From Trial Expected in September 2022
nhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE: MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD).
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system,
LEBANON, Tenn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (NASDAQ:DCFC), a global leader in direct current (DC) fast chargers for electric vehicles (EVs), today celebrates the opening of its new EV fast